CA2108569A1 - Polysaccharides sulfates utilises comme inhibiteurs de la proliferation des cellules musculaires lisses - Google Patents

Polysaccharides sulfates utilises comme inhibiteurs de la proliferation des cellules musculaires lisses

Info

Publication number
CA2108569A1
CA2108569A1 CA002108569A CA2108569A CA2108569A1 CA 2108569 A1 CA2108569 A1 CA 2108569A1 CA 002108569 A CA002108569 A CA 002108569A CA 2108569 A CA2108569 A CA 2108569A CA 2108569 A1 CA2108569 A1 CA 2108569A1
Authority
CA
Canada
Prior art keywords
so3r
mixture
smooth muscle
heparin
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002108569A
Other languages
English (en)
Inventor
H. Edward Conrad
Brian K. Brandley
Lun H. Lam
Roger A. Laine
Peter Fugedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycomed Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2108569A1 publication Critical patent/CA2108569A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002108569A 1991-04-17 1992-04-15 Polysaccharides sulfates utilises comme inhibiteurs de la proliferation des cellules musculaires lisses Abandoned CA2108569A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68654091A 1991-04-17 1991-04-17
US686,540 1991-04-17

Publications (1)

Publication Number Publication Date
CA2108569A1 true CA2108569A1 (fr) 1992-10-18

Family

ID=24756732

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002108569A Abandoned CA2108569A1 (fr) 1991-04-17 1992-04-15 Polysaccharides sulfates utilises comme inhibiteurs de la proliferation des cellules musculaires lisses

Country Status (6)

Country Link
EP (1) EP0582665A1 (fr)
JP (1) JPH06506973A (fr)
AU (1) AU1902592A (fr)
CA (1) CA2108569A1 (fr)
NO (1) NO933699L (fr)
WO (1) WO1992018546A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5888984A (en) * 1994-05-12 1999-03-30 Dermal Research Laboratories, Inc. Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
AUPO556297A0 (en) * 1997-03-11 1997-04-10 Australian National University, The Sulfated oligosaccharides having anticoagulant/ antithrombotic activity
AUPO888497A0 (en) 1997-09-01 1997-09-25 Australian National University, The Use of sulfated oligosaccharides as inhibitors of cardiovascular disease
AUPO976897A0 (en) 1997-10-14 1997-11-06 Australian National University, The Use of sulfated oligosaccharides in lowering blood triglyceride levels
CA2361268C (fr) 1999-02-01 2014-06-10 Dermal Research Laboratories, Inc. Composition pharmaceutique d'hydrates de carbone complexes et d'huiles essentielles et methode d'utilisation de celle-ci
US7879824B2 (en) 2001-07-31 2011-02-01 Dermal Research Laboratories, Inc. Methods of preventing or treating diseases and conditions using complex carbohydrates
EP1731131A1 (fr) * 2004-03-29 2006-12-13 Kringle Pharma Inc. Accelerateur de production hgf contenant un oligosaccharide de type heparine
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949115B1 (fr) * 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL61201A (en) * 1979-10-05 1984-09-30 Choay Sa Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
NO933699D0 (no) 1993-10-14
AU1902592A (en) 1992-11-17
WO1992018546A1 (fr) 1992-10-29
NO933699L (no) 1993-12-07
EP0582665A1 (fr) 1994-02-16
JPH06506973A (ja) 1994-08-04

Similar Documents

Publication Publication Date Title
US5380716A (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
US5250519A (en) Non-anticoagulant heparin derivatives
US5013724A (en) Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications
US5280016A (en) Non-anticoagulant heparin derivatives
WO1982001005A1 (fr) Oligosaccharides ayant une activite d'anticoagulation selective
CA2132750A1 (fr) Oligosaccharides presentant une grand affinite de liaison avec des facteurs de croissance
KR20040048404A (ko) 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체
CA2108569A1 (fr) Polysaccharides sulfates utilises comme inhibiteurs de la proliferation des cellules musculaires lisses
EP1095657B1 (fr) Compositions pour la régulation de l'activité des cytokines
Garg et al. Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation
AU2003240190B2 (en) Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation
US7618652B2 (en) Glycosaminoglycan anticoagulants derived from fish
JP4462826B2 (ja) 骨疾患治療剤
WO1992017506A1 (fr) Modulation de l'activite de l'activateur du plasminogene tissulaire a l'aide de fragments d'heparine
Noti et al. Synthetic approach to define structure-activity relationship of heparin and heparan sulfate
RU2333222C2 (ru) Эпимеризованные производные полисахарида к5 с высокой степенью сульфатирования
Garg et al. Synthetic Approach to Define Structure—Activity Relationship of Heparin and Heparan Sulfate
ZA200410359B (en) Epimerized derivatives of K5 polysaccharide with a very high degree of sulfation.
MXPA97008289A (en) Preparation and use of oligosacaridos sulfata

Legal Events

Date Code Title Description
FZDE Dead